Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cristina Colon-Del Toro

Psychiatry Miami, FL Medical Doctor

NPI 1033536131 CMS profile 6697121

10300 Sw 216Th St, Miami, FL 33190

Open in the dashboard

General payments

$5,305

221 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cristina Colon-Del Toro of Miami, FL is reported in the CMS Open Payments database as having received $5,305 across 221 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $846 39
2024 General $712 33
2023 General $604 27
2022 General $585 29
2021 General $1,116 51
2020 General $815 28
2019 General $627 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cristina Colon-Del Toro
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Cristina Colon-Del Toro were reported at $846. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Cristina Colon-Del Toro Psychiatry median Middle half National median
2019 $627 $184 $59–$605 $163
2020 $815 $119 $36–$372 $114
2021 $1,116 $143 $43–$576 $132
2022 $585 $153 $50–$590 $149
2023 $604 $170 $56–$651 $160
2024 $712 $179 $57–$673 $164
2025 $846 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $818 28 payments
  2. Alkermes, Inc. $771 37 payments
  3. Teva Pharmaceuticals USA, Inc. $613 27 payments
  4. Sunovion Pharmaceuticals Inc. $595 13 payments
  5. Otsuka America Pharmaceutical, Inc. $556 28 payments
  6. Janssen Pharmaceuticals, Inc $416 22 payments
  7. AbbVie, Inc. $411 26 payments
  8. Indivior Inc. $321 12 payments
  9. Allergan Inc. $271 9 payments
  10. E.R. Squibb & Sons, L.L.C. $262 11 payments
  11. Other $271 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,275 220 payments
  2. Education $30 1 payment
Products named General payments · program years 2019–2025
  1. ARISTADA Cns $684 33 payments
  2. ARISTADA Cns $684 33 payments
  3. LATUDA $595 13 payments
  4. ARISTADA Cns $574 28 payments
  5. ARISTADA Cns $574 28 payments
  6. LYBALVI $535 25 payments
  7. AUSTEDO $389 17 payments
  8. INGREZZA $347 9 payments
  9. VRAYLAR $346 13 payments
  10. INVEGA SUSTENNA $328 17 payments
  11. Other $3,260 151 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

981

Median for Psychiatry: 574

Drug cost

$175,040

Median for Psychiatry: $27,624

Branded share of claims

9.8%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Xr Deutetrabenazine Brand 13 $77,077
Perseris Risperidone Brand 11 $30,891
Abilify Maintena Aripiprazole Brand 12 $28,752
Lybalvi Olanzapine/Samidorphan Malate Brand 13 $15,088
Lurasidone Hcl Generic 34 $10,554
Aripiprazole Generic 36 $3,474
Trazodone Hcl Generic 102 $810
Haloperidol Decanoate Generic 13 $730
Fluphenazine Hcl Generic 12 $644
Risperidone Generic 70 $627

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PERSERIS
  • Indivior Inc. $133
$133 11 —
VRAYLAR
  • AbbVie, Inc. $93
$93 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $91
$91 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $73
$73 — —
ARISTADA
  • Alkermes, Inc. $72
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record